Shanghai De Novo Pharmatech is a clinical stage, biotech company. Building on our extensive in-house capability in pharmaceutical chemistry and translational medicine, we have established an internationally competitive oncology pipeline, with two leading innate immune agonists at clinical stage.

 l  DN1508052, a potentially FIC TLR8 agonist currently in phase I in US and China.

 l  DN015089, a potentially BIC STING agonist currently in phase I in China.

Both candidates have great potential as a monotherapy and in combination with immune checkpoint inhibitor, such as PD-1, etc., and are being evalsuated in several ongoing and planned clinical studies with advanced solid tumor.

To widen therapeutic window by deliver immune agonist precisely, we are in the process of building an ISAC technology platform, two ISAC drug candidates are in discovery stage now.